Cost-effectiveness of varicella vaccination programs: An update of the literature

Expert Review of Vaccines

Volumn 7, Issue 6, 2008, Pages 753-782

  Rozenbaum, Mark H ^a   Van Hoek, Albert Jan ^b   Vegter, Stefan ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Chickenpox; Cost effectiveness; Dynamic; Health economics; Herpes zoster; Modeling; Static; Vaccination; Varicella

Indexed keywords

CHICKENPOX VACCINE;

CHICKENPOX; CHILDHOOD DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG DOSE; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; INFECTION SENSITIVITY; MEDICAL LITERATURE; OCCUPATIONAL HAZARD; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; INCIDENCE; INFANT; MIDDLE AGED;

EID: 49449115678     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.6.753     Document Type: Review

References (111)

1. Chant KG, Sullivan EA, Burgess MA et al. Varicella-zoster virus infection in Australia. Aust. NZ J. Public Health 22(4), 413-418 (1998).
2. Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J. Infect. Dis. 182(2), 383-390 (2000).
3. Rawson H, Crampin A, Noah N. Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 323(7321), 1091-1093 (2001).
4. Marchetto S, de Benedictis FM, de Martino M et al. Epidemiology of hospital admissions for chickenpox in children: an Italian multicentre study in the pre-vaccine era. Acta Paediatr. 96(10), 1490-1493 (2007).
5. Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J. Infect. Dis. 172(3), 706-712 (1995).
6. Robert Koch Institute. Allgemeine impfung gegen windpocken (varizellen?). Epidemiol. Bull. 11, 79-82 (2003).
7. Sengupta N, Booy R, Schmitt HJ et al. Varicella vaccination in Europe: are we ready for a universal childhood programme? Eur. J. Pediatr. 2007.
8. Office for National Statistics. Twentieth Century Mortality. HMSO, London, UK (2000).
9. Postma MJ, Bos JM, Welte R et al. Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations. Eur. J. Health Econ. 5(1), 54-57 (2004).
10. Brisson M, Edmunds WJ, Gay NJ, Miller E. Varicella vaccine and shingles. JAMA 287(17), 2211-2212 (2002).
11. Seward JF, Jumaan AO, Galli K, Wharton M. Varicella vaccine and shingles. JAMA 287(17), 2211-2212 (2007).
12. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58, 9-20 (1965).
13. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20(19-20), 2500-2507 (2002).
14. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360(9334), 678-682 (2002).
15. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis. 191(12), 2002-2007 (2005).
16. Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine 20(7-8), 1113-1125 (2002).
17. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin. Proc. 82(11), 1341-1349 (2007).
18. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19(23-24), 3076-3090 (2001).
19. Asano Y. Varicella vaccine: the Japanese experience. J. Infect. Dis. 174(Suppl. 3), S310-S313 (1996).
20. Weibel RE, Neff BJ, Kuter BJ et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N. Engl. J. Med. 310(22), 1409-1415 (1984).
21. Kuter BJ, Weibel RE, Guess HA et al. Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 9(9), 643-647 (1991).
22. Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J. Pediatr. 127(4), 518-525 (1995).
23. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 78(4 Pt 2), 748-756 (1986).
24. White CJ, Kuter BJ, Hildebrand CS et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 87(5), 604-610 (1991).
25. Heininger U, Seward JF. Varicella. Lancet 368(9544), 1365-1376 (2006).
26. Centers for Disease Control and Prevention. Prevention of varicella. MMWR Recomm. Rep. 56(RR-4), 1-40 (2007).
27. Takahashi M. 25 years' experience with the Biken Oka strain varicella vaccine: a clinical overview. Paediatr. Drugs 3(4), 285-292 (2001).
28. Brisson M, Edmunds WJ, Gay NJ, Law B, De SG. Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 18(25), 2775-2778 (2000).
29. Kuter BJ, Ngai A, Patterson CM et al. Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 13(11), 967-972 (1995).
30. American Academy of Pediatrics. Committee on Infectious Diseases. Varicella vaccine update. Pediatrics 105(1 Pt 1), 136-141 (2000).
31. Bayer O, Heininger U, Heiligensetzer C, von KR. Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine 25(37-38), 6655-6660 (2007).
32. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med. Decis. Making 23(1), 76-82 (2003). • Describes the effect of herd immunity, explaining the main differences between static and dynamic models.
33. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat. Med. 18(23), 3263-3282 (1999).
34. Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 319(7223), 1462-1467 (1999).
35. Brisson M, Edmunds WJ, Gay NJ, Law B, De SG. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol. Infect. 125(3), 651-669 (2000).
36. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J. Med. Virol. 70(Suppl. 1), S31-S37 (2003).
37. Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis. Child. 88(10), 862-869 (2003).
38. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N. Engl. J. Med. 325(22), 1545-1550 (1991).
39. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J. Gen. Intern. Med. 20(8), 748-753 (2005).
40. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. Incidence of herpes zoster, 1997-2002. Epidemiol. Infect. 133(2), 245-253 (2005).
41. Wagenpfeil S, Neiss A, Wutzler P. Effects of varicella vaccination on herpes zoster incidence. Clin. Microbiol. Infect. 10(11), 954-960 (2004).
42. Yih WK, Brooks DR, Lett SM et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 5(1), 68 (2005).
43. Goldman GS. Cost-benefit analysis of universal varicella vaccination in the U.S. taking into account the closely related herpes-zoster epidemiology. Vaccine 23(25), 3349-3355 (2005).
44. Solomon BA, Kaporis AG, Glass AT, Simon SI, Baldwin HE. Lasting Immunity to Varicella in Doctors study (L.I.V.I.D. study). J. Am. Acad. Dermatol. 38(5 Pt 1), 763-765 (1998).
45. Terada K, Hiraga Y, Kawano S, Kataoka N. [Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster]. Kansenshogaku Zasshi 69(8), 908-912 (1995).
46. Thiry N, Beutels P, Van DP, Van DE. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21(1), 13-38 (2003).
47. Diez DJ, Ridao M, Latour J, Ballester A, Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17(11-12), 1306-1311 (1999).
48. Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J. Pediatr. 124(6), 869-874 (1994).
49. Preblud SR, Orenstein WA, Koplan JP, Bart KJ, Hinman AR. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad. Med. J. 61(Suppl. 4), 17-22 (1985).
50. Scuffham P, Devlin N, Eberhart-Phillips J, Wilson-Salt R. The cost-effectiveness of introducing a varicella vaccine to the New Zealand immunisation schedule. Soc. Sci. Med. 49(6), 763-779 (1999).
51. Coudeville L, Paree F, Lebrun T, Sailly J. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 17(2), 142-151 (1999).
52. Lieu TA, Finkler LJ, Sorel ME, Black SB, Shinefield HR. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics 95(5), 632-638 (1995).
53. Beutels P, Clara R, Tormans G, Van DE, Van DP. Costs and benefits of routine varicella vaccination in German children. J. Infect. Dis. 174(Suppl. 3), S335-S341 (1996).
54. Getsios D, Caro JJ, Caro G et al. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr. Infect. Dis. J. 21(6), 542-547 (2002).
55. Scuffham PA, Lowin AV, Burgess MA. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine 18(5-6), 407-415 (1999).
56. Gayman J. A cost-effectiveness model for analyzing two varicella vaccination strategies. Am. J. Health Syst. Pharm. 55(24 Suppl. 4), S4-S8 (1998).
57. Nettleman MD, Schmid M. Controlling varicella in the healthcare setting: the cost effectiveness of using varicella vaccine in healthcare workers. Infect. Control Hosp. Epidemiol. 18(7), 504-508 (1997).
58. Gray AM, Fenn P, Weinberg J, Miller E, McGuire A. An economic analysis of varicella vaccination for health care workers. Epidemiol. Infect. 119(2), 209-220 (1997).
59. Kitai IC, King S, Gafni A. An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients. Clin. Infect. Dis. 17(3), 441-447 (1993).
60. Smith KJ, Roberts MS. Cost effectiveness of vaccination strategies in adults without a history of chickenpox. Am. J. Med. 108(9), 723-729 (2000).
61. Howell MR, Lee T, Gaydos CA, Nang RN. The cost-effectiveness of varicella screening and vaccination in U.S. Army recruits. Mil. Med. 165(4), 309-315 (2000).
62. Burnham BR, Wells TS, Riddle JR. A cost-benefit analysis of a routine varicella vaccination program for United States Air Force Academy cadets. Mil. Med. 163(9), 631-634 (1998).
63. Smith WJ, Jackson LA, Watts DH, Koepsell TD. Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet. Gynecol. 92(4 Pt 1), 535-545 (1998).
64. Sugawara T, Ohkusa Y, Oikawa K et al. [Cost-effectiveness analysis of routine immunization for varicella in Japan]. Kansenshogaku Zasshi 80(3), 212-219 (2006).
65. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA 294(7), 797-802 (2005).
66. Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med. Microbiol. Immunol. 191(2), 89-96 (2002).
67. Knuf M, Neiss A, Wutzler P. [Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis]. Klin. Padiatr. 218(4), 203-212 (2006).
68. Banz K, Wagenpfeil S, Neiss A et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21(11-12), 1256-1267 (2003).
69. O'Neill J, Buttery J. Varicella and paediatric staff: current practice and vaccine cost-effectiveness. J. Hosp. Infect. 53(2), 117-119 (2003).
70. Pinot de MA, Edmunds WJ, Breuer J. The cost-effectiveness of antenatal varicella screening with post-partum vaccination of susceptibles. Vaccine 24(9), 1298-1307 (2006).
71. Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics 22(13), 839-855 (2004).
72. Gialloreti LE, Divizia M, Pica F, Volpi A. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy. Herpes 12(2), 33-37 (2005).
73. Thiry N, Beutels P, Tancredi F et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine 22(27-28), 3546-3562 (2004). • Pharmacoeconomic study on vaccination of 11-year-olds.
74. Hammerschmidt T, Bisanz H, Wutzler P. Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Vaccine 25(42), 7307-7312 (2007).
75. Lenne X, Diez DJ, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain: results from a dynamic model. Vaccine 24(47-48), 6980-6989 (2006).
76. Pena-Rey I, Perez-Farinos N, Cortes-Garcia M, Amela-Heras C. [Cost-effectiveness of varicella vaccination in Spanish adolescents]. Gac. Sanit. 18(4), 287-294 (2004).
77. Coudeville L, Brunot A, Szucs TD, Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health 8(3), 209-222 (2005). • Uses a dynamic model to investigate the cost-effectiveness of vaccination in two different countries.
78. Hanslik T, Boelle PY, Schwarzinger M et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine 21(25-26), 3614-3622 (2003).
79. Hudeckova H, Straka S, Rusnakova S. Epidemiological features and economic evaluation of a potential chickenpox vaccination strategy in Slovak Republic. Cent. Eur. J. Public Health 8(4), 227-228 (2000).
80. Figueira M, Christiansen D, Barnett ED. Cost-effectiveness of serotesting compared with universal immunization for varicella in refugee children from six geographic regions. J. Travel Med. 10(4), 203-207 (2003).
81. Olson AD, Shope TC, Flynn JT. Pretransplant varicella vaccination is cost-effective in pediatric renal transplantation. Pediatr. Transplant. 5(1), 44-50 (2001).
82. Jean-Jasmin LM, Lynette SP, Stefan M, Kai CS, Chew FT, Wah LB. Economic burden of varicella in Singapore - a cost benefit estimate of implementation of a routine varicella vaccination. Southeast Asian J. Trop. Med. Public Health 35(3), 693-696 (2004).
83. Hsu HC, Lin RS, Tung TH, Chen TH. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine 21(25-26), 3982-3987 (2003).
84. Tseng HF, Tan HF, Chang CK. Varicella epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan. Southeast Asian J. Trop. Med. Public Health 36(6), 1450-1458 (2005).
85. Chodick G, Ashkenazi S, Livni G, Lerman Y. Cost-effectiveness of varicella vaccination of healthcare workers. Vaccine 23(43), 5064-5072 (2005).
86. Merrett P, Schwartzman K, Rivest P, Greenaway C. Strategies to prevent varicella among newly arrived adult immigrants and refugees: a cost-effectiveness analysis. Clin. Infect. Dis. 44(8), 1040-1048 (2007).
87. Ginsberg GM, Somekh E. Cost containment analysis of childhood vaccination against varicella in Israel. J. Infect. 48(2), 119-133 (2004).
88. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 23(7), 639-649 (2005).
89. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd Edition). Oxford University Press, Oxford, UK (2005).
90. Bos JM, Beutels P, Annemans L, Postma MJ. Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases. Pharmacoeconomics 22(18), 1171-1179 (2004).
91. Annemans L, Bos JM, Postma MJ. Discounting health effects in pharmacoeconomic evaluations: some additional element to consider. ISPOR Connections 9(4), 3-5 (2003).
92. Lieu TA, Cochi SL, Black SB et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 271(5), 375-381 (1994).
93. Brisson M, Edmunds WJ. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med. Decis. Making 26(5), 434-446 (2006).
94. Daz-Mitoma F, Halperin SA, Scheifele D. Reactogenicity to a live attenuated varicella vaccine in Canadian children. Can. J. Infect. Dis. 11(2), 97-101 (2000).
95. Boot HJ, de Melker HE, Stolk EA, de Wit GA, Kimman TG. Assessing the introduction of universal varicella vaccination in The Netherlands. Vaccine 24(37-39), 6288-6299 (2006).
96. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J. Infect. Dis. 197(Suppl. 2), S228-S236 (2008).
97. Pellissier JM, Brisson M, Levin MJ. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine 25(49), 8326-8337 (2007).
98. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 19(23-24), 3076-3090 (2001). • One of the first studies taking the potential impact of vaccination on zoster into account.
99. Hornberger J, Robertus K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Ann. Intern. Med. 145(5), 317-325 (2006).
100. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin. Infect. Dis. 44(10), 1280-1288 (2007).
101. Hethcote HW. The mathematics of infectious diseases. SIAM J. 42, 599-653 (2000).
102. Hamer H. Epidemic disease in England. Lancet 1, 733-739 (1906).
103. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford, UK (1991).
104. Postma MJ. Pharmacoeconomic research. Pharm. World Sci. 25(6), 245-246 (2003).
105. Postma MJ, de VR, Welte R, Edmunds J. Health economic methodology illustrated with recent work on chlamydia screening: the concept of extended dominance. Sex. Transm. Infect. 84, 152-154 (2008).
106. The Statistical Office of the European Communities (Eurostat) http://epp.eurostat.ec.europa.eu
107. Central Bureau of Statistics www.cbs.gov.il
108. Bureau of Labor Statistics Data www.bls.gov/data/home
109. The Canadian Central Bank www.bankofcanada.ca
110. The European Central Bank www.ecb.int
111. International Society for Pharmacoeconomics and Outcomes Research www.ispor.org